Quebec, Canada-based Valeant Pharmaceuticals (NYSE: VRX) has entered into an amended agreement to remain lead bidder in the acquisition of Dendreon and its product Provenge (sipuleucel-T).
Valeant has raised its offer to $400 million in cash for the assets as part of its amended and restated "stalking horse" asset purchase.
The company previously announced that it had entered into an asset purchase agreement in a sale process being conducted under Section 363 of the US Bankruptcy Code. The new agreement increases the purchase price from the originally-stated $296 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze